image

Pipeline Overview

Innovative Drugs Designed to Improve Patients’ Lives

Our clinical-stage pipeline includes four internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies and solid tumors. It comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that target key control elements in immune regulation (Targeted Protein Elevation). Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of Targeted Protein Degraders against a set of unique targets.

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryIND enablingPhase 1Phase 2Phase 3
Clinical Pipeline
NX-2127 Degrader BTK + IKZF B-cell malignancies

 

NX-5948 Degrader BTK (Oral) B-cell malignancies and autoimmune disease

 

NX-1607 Inhibitor CBL-B (Oral) Immuno-oncology

 

DeTIL-0255 Cell Therapy Adoptive cell therapy with ex vivo CBL-B inhibition Gynecologic malignancies

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryIND enablingPhase 1Phase 2Phase 3
Discovery Pipeline
Wholly Owned Multiple targets* Undisclosed

 

Gilead Sciences 5 targets Undisclosed

 

Sanofi 5 targets Undisclosed

 

Candidate / TargetPhase
Clinical Pipeline
NX-2127 Degrader
BTK + IKZF
Phase 1
NX-5948 Degrader
BTK (Oral)
Phase 1
NX-1607 Inhibitor
CBL-B (Oral)
Phase 1
DeTIL-0255 Cell Therapy
Adoptive cell therapy with ex vivo CBL-B inhibition
Phase 1
Discovery Pipeline
Wholly Owned
Multiple targets*
Discovery
Gilead Sciences
5 targets
Discovery
Sanofi
5 targets
Discovery

Degraders and inhibitors of multiple targets including E3 ligases, T cell kinase, hematology & oncology drivers, and viral proteins